Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results

被引:16
|
作者
Lambrecht, Marie [1 ,3 ]
Clementel, Enrico [2 ]
Sonke, Jan-Jacob [3 ]
Nestle, Ursula [4 ,5 ]
Adebahr, Sonja [5 ,6 ,7 ]
Guckenberger, Mathias [8 ]
Andratschke, Nicolaus [8 ]
Weber, Damien C. [8 ,9 ]
Verheij, Marcel [3 ]
Hurkmans, Coen W. [1 ]
机构
[1] Catharina Hosp, Dept Radiat Oncol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[2] EORTC Headquarters, Dept Qual Assurance, Brussels, Belgium
[3] Netherland Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands
[4] Kliniken Maria Hilf GmbH Monchengladbach, Dept Radiat Oncol, Monchengladbach, Germany
[5] Univ Freiburg, Fac Med, Med Ctr, Dept Radiat Oncol, Freiburg, Germany
[6] German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany
[7] German Canc Res Ctr, Heidelberg, Germany
[8] Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland
[9] Paul Scherrer Inst, ETH Domain, Ctr Proton Therapy, Villigen, Switzerland
关键词
Benchmark; SBRT; Lung; Planning exercise; Clinical trial; RADIATION; ATLAS;
D O I
10.1016/j.radonc.2018.10.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To report on the benchmark case (BC) study performed in the context of the European Organisation for Research and Treatment of Cancer prospective multicentre Lungtech trial of SBRT for patients with inoperable centrally located lung tumours. Methods and materials: Target volume and organs at risk (OARs) delineations first needed to be acceptable before the treatment plan was reviewed. Retrospectively, Dice similarity coefficients of the OARs and the target volumes were calculated and a set of gold standard contours adapted for each institution margins was applied on the accepted dose submissions to evaluate the influence of acceptable delineation variations on dosimetry. Results: Twenty-five institutions participated. Five BCs were accepted at the first attempt. Twenty institutions had to revise their delineation at least once and seven had to revise their planning once. The V-60 Gy dose coverage improved significantly (p = 0.05) between the first and final submissions from median (range) 94.8% (22.5-97.8) to 95.3% (70.5-99.3). The median Dice coefficient varied significantly between OARs: The lowest values were found for the brachial plexus 0.25 (0.01-0.54) and the highest for the spinal cord 0.89 (0.71-0.95). The mean PTV Dice coefficient was 0.82 (0.48-0.92). Applying the gold standard contours, only one institution remained compliant with the dose coverage criteria with V-60 Gy median (range) of 83.4% (54.2-93.9). Conclusions: Clinical guidelines and radiotherapy protocols are not a substitute for timely radiotherapy quality assurance procedures, which improve dose coverage significantly. Delineation remains the main source of BC rejection and plan review without first reviewing delineation may not be efficient. Our results show that delineation variations seem to have a larger influence on PTV coverage than variations in planning and irradiation techniques and thus suggest that dose tolerance criteria should preferably take into account the accuracy of delineation. (C) 2018 Published by Elsevier B.V.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 50 条
  • [1] Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours – a clinical physics perspective
    Marie Lambrecht
    Christos Melidis
    Jan-Jakob Sonke
    Sonja Adebahr
    Ronald Boellaard
    Marcel Verheij
    Matthias Guckenberger
    Ursula Nestle
    Coen Hurkmans
    Radiation Oncology, 11
  • [2] Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours - a clinical physics perspective
    Lambrecht, Marie
    Melidis, Christos
    Sonke, Jan-Jakob
    Adebahr, Sonja
    Boellaard, Ronald
    Verheij, Marcel
    Guckenberger, Matthias
    Nestle, Ursula
    Hurkmans, Coen
    RADIATION ONCOLOGY, 2016, 11
  • [3] Benchmark Case results from the EORTC Lungtech trial of SBRT for patients with centrally NSCLC
    Lambrecht, M.
    Clement, E.
    Sonke, J. J.
    Nestle, U.
    Adebahr, S.
    Guckenberger, M.
    Weber, D. C.
    Hurkmans, C. W.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S108 - S109
  • [4] LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective
    Adebahr, S.
    Collette, S.
    Shash, E.
    Lambrecht, M.
    Le Pechoux, C.
    Faivre-Finn, C.
    De Ruysscher, D.
    Peulen, H.
    Belderbos, J.
    Dziadziuszko, R.
    Fink, C.
    Guckenberger, M.
    Hurkmans, C.
    Nestle, U.
    BRITISH JOURNAL OF RADIOLOGY, 2015, 88 (1051):
  • [6] Quality assurance of 4DCT in the EORTC Lungtech trial on SBRT for patients with NSCLC
    Lambrecht, M.
    Sonke, J. J.
    Nestle, U.
    Peulen, H.
    Weber, D.
    Verheij, M.
    Hurkmans, C. W.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S532 - S533
  • [7] Quality assurance of four-dimensional computed tomography in a multicentre trial of stereotactic body radiotherapy of centrally located lung tumours
    Lambrecht, Marie
    Sonke, Jan-Jakob
    Nestle, Ursula
    Peulen, Heike
    Weber, Damien C.
    Verheij, Marcel
    Hurkmans, Coen W.
    PHYSICS & IMAGING IN RADIATION ONCOLOGY, 2018, 8 : 57 - 62
  • [8] LungTech stereotactic body radiotherapy (SBRT) of inoperable centrally located NSCLC: a phase II study in preparation for a randomised phase III trial
    Falk, S.
    Faivre-Finn, C.
    LUNG CANCER, 2015, 87 : S71 - S71
  • [9] LungTech Stereotactic Body Radiotherapy (SBRT) of inoperable centrally located NSCLC: A phase II study in preparation for a randomised phase III trial
    Faivre-Finn, C.
    Ahmed, M.
    Franks, K.
    Ahmad, S.
    Harrow, S.
    LUNG CANCER, 2017, 103 : S74 - S75
  • [10] Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results
    Levy, Antonin
    Adebahr, Sonja
    Hurkmans, Coen
    Ahmed, Merina
    Ahmad, Shahreen
    Guckenberger, Matthias
    Geets, Xavier
    Lievens, Yolande
    Lambrecht, Maarten
    Pourel, Nicolas
    Lewitzki, Victor
    Konopa, Krzysztof
    Franks, Kevin
    Dziadziuszko, Rafal
    McDonald, Fiona
    Fortpied, Catherine
    Clementel, Enrico
    Fournier, Beatrice
    Rizzo, Stefania
    Fink, Christian
    Riesterer, Oliver
    Peulen, Heike
    Andratschke, Nicolaus
    McWilliam, Alan
    Gkika, Eleni
    Schimek-Jasch, Tanja
    Grosu, Anca-Ligia
    Le Pechoux, Cecile
    Faivre-Finn, Corinne
    Nestle, Ursula
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09) : 1297 - 1309